Only thirty percent (30%) of patients on PCSK9 inhibitors achieve ESC/EAS LDL-cholesterol guideline treatment targets in a lipid clinic: Real world data
| Autor: | Bolodeoku, J., Morris, K., Whitehead, S. |
|---|---|
| Zdroj: | In Atherosclerosis August 2023 379 Supplement 1:S65-S65 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect